CD40 signaling in CD8+CD40+ T cells turns on contra-T regulatory cell functions

Journal of Immunology

Volumn 184, Issue 10, 2010, Pages 5510-5518

  Martin, Sunil ^a   Pahari, Sushmita ^a   Sudan, Raki ^a   Saha, Bhaskar ^a  

^a NATIONAL CENTRE FOR CELL SCIENCE   (India)

Author keywords

[No Author keywords available]

Indexed keywords

CD40 ANTIGEN; CD8 ANTIGEN; GRANZYME; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 10; INTERLEUKIN 7 RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; PERFORIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE C; RAS PROTEIN;

ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOKINE PRODUCTION; IMMUNOMODULATION; INFECTION RESISTANCE; KNOCKOUT MOUSE; LEISHMANIA DONOVANI; LEISHMANIASIS; LYMPHOCYTE PROLIFERATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; SIGNAL TRANSDUCTION; T LYMPHOCYTE ACTIVATION; ANIMAL; APOPTOSIS; BAGG ALBINO MOUSE; BIOSYNTHESIS; CD8+ T LYMPHOCYTE; CELL COMMUNICATION; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; DISEASE MODEL; GENETIC PREDISPOSITION; GENETICS; GROWTH, DEVELOPMENT AND AGING; HOSPITALIZATION; IMMUNOLOGY; METABOLISM; MOUSE MUTANT; PARASITOLOGY; PATHOLOGY; PHYSIOLOGY; TRANSPLANTATION; VISCERAL LEISHMANIASIS;

ADOPTIVE TRANSFER; ANIMALS; ANTIGENS, CD40; APOPTOSIS; CD8-POSITIVE T-LYMPHOCYTES; CELL COMMUNICATION; CYTOTOXICITY, IMMUNOLOGIC; DISEASE MODELS, ANIMAL; GENETIC PREDISPOSITION TO DISEASE; GRANZYMES; LEISHMANIA DONOVANI; LEISHMANIASIS, VISCERAL; MICE; MICE, INBRED BALB C; MICE, KNOCKOUT; PERFORIN; SEVERITY OF ILLNESS INDEX; SIGNAL TRANSDUCTION; T-LYMPHOCYTES, CYTOTOXIC; T-LYMPHOCYTES, REGULATORY;

EID: 77954718056     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.0902762     Document Type: Article

References (47)

1. Cools, N., P. Ponsaerts, V. F. Van Tendeloo, and Z. N. Berneman. 2007. Regulatory T cells and human disease. Clin. Dev. Immunol. 2007: 89195.
2. Banham, A. H. 2006. Cell-surface IL-7 receptor expression facilitates the purification of FOXP3(+) regulatory T cells. Trends Immunol. 27: 541-544.
3. Curotto de Lafaille, M. A., and J. J. Lafaille. 2009. Natural and adaptive foxp3+ regulatory T cells: more of the same or a division of labor? Immunity 30: 626-635.
4. Shevach, E. M. 2009. Mechanisms of foxp3+ T regulatory cell-mediated suppression. Immunity 30: 636-645.
5. Castellino, F., and R. N. Germain. 2006. Cooperation between CD4+ and CD8+ T cells: when, where, and how. Annu. Rev. Immunol. 24: 519-540.
6. Rocha, P. N., T. J. Plumb, S. D. Crowley, and T. M. Coffman. 2003. Effector mechanisms in transplant rejection. Immunol. Rev. 196: 51-64.
7. Tsai, S., A. Shameli, and P. Santamaria. 2008. CD8+ T cells in type 1 diabetes. Adv. Immunol. 100: 79-124.
8. Doherty, P. C., and J. P. Christensen. 2000. Accessing complexity: the dynamics of virus-specific T cell responses. Annu. Rev. Immunol. 18: 561-592.
9. Wong, P., and E. G. Pamer. 2003. CD8 T cell responses to infectious pathogens. Annu. Rev. Immunol. 21: 29-70.
10. Boon,T., J. C.Cerottini,B.Van den Eynde, P. van der Bruggen, and A.Van Pel. 1994. Tumor antigens recognized by T lymphocytes. Annu. Rev. Immunol. 12: 337-365.
11. Bodas, M., N. Jain, A. Awasthi, S. Martin, R. K. Penke Loka, D. Dandekar, D. Mitra, and B. Saha. 2006. Inhibition of IL-2 induced IL-10 production as a principle of phase-specific immunotherapy. J. Immunol. 177: 4636-4643. (Pubitemid 44469796)
12. Kamanaka, M., P. Yu, T. Yasui, K. Yoshida, T. Kawabe, T. Horii, T. Kishimoto, and H. Kikutani. 1996. Protective role of CD40 in Leishmania major infection at two distinct phases of cell-mediated immunity. Immunity 4: 275-281. (Pubitemid 26131010)
13. Awasthi, A., R. Mathur, A. Khan, B. N. Joshi, N. Jain, S. Sawant, R. Boppana, D. Mitra, and B. Saha. 2003. CD40 signaling is impaired in L. major-infected macrophages and is rescued by a p38MAPK activator establishing a host-protective memory T cell response. J. Exp. Med. 197: 1037-1043.
14. Mathur, R. K., A. Awasthi, P. Wadhone, B. Ramanamurthy, and B. Saha. 2004. Reciprocal CD40 signals through p38MAPK and ERK-1/2 induce counteracting immune responses. Nat. Med. 10: 540-544.
15. Rub, A., R. Dey, M. Jadhav, R. Kamat, S. Chakkaramakkil, S. Majumdar, R. Mukhopadhyaya, and B. Saha. 2009. Cholesterol depletion associated with Leishmania major infection alters macrophage CD40 signalosome composition and effector function. Nat. Immunol. 10: 273-280.
16. Joshi, T., S. Rodriguez, V. Perovic, I. A. Cockburn, and S. Stäger. 2009. B7-H1 blockade increases survival of dysfunctional CD8(+) T cells and confers protection against Leishmania donovani infections. PLoS Pathog. 5: e1000431.
17. Basu, R., S. Bhaumik, A. K. Haldar, K. Naskar, T. De, S. K. Dana, P. Walden, and S. Roy. 2007. Hybrid cell vaccination resolves Leishmania donovani infection by eliciting a strong CD8+ cytotoxic T-lymphocyte response with concomitant suppression of interleukin-10 (IL-10) but not IL-4 or IL-13. Infect. Immun. 75: 5956-5966.
18. Polley, R., S. Stager, S. Prickett, A. Maroof, S. Zubairi, D. F. Smith, and P. M. Kaye. 2006. Adoptive immunotherapy against experimental visceral leishmaniasis with CD8+ T cells requires the presence of cognate antigen. Infect. Immun. 74: 773-776.
19. Borrow, P.,A. Tishon, S. Lee, J. Xu, I. S. Grewal, M. B. Oldstone, and R. A. Flavell. 1996. CD40L-deficient mice show deficits in antiviral immunity and have an impaired memory CD8+ CTL response. J. Exp. Med. 183: 2129-2142.
20. Grewal, I. S., J. Xu, and R. A. Flavell. 1995. Impairment of antigen-specific T-cell priming in mice lacking CD40 ligand. Nature 378: 617-620.
21. Saha, B., H. Nanda-Roy, A. Pakrashi, R. N. Chakrabarti, and S. Roy. 1991. Immunobiological studies on experimental visceral leishmaniasis. I. Changes in lymphoid organs and their possible role in pathogenesis. Eur. J. Immunol. 21: 577-581.
22. Murray, H. W., C. M. Lu, E. B. Brooks, R. E. Fichtl, J. L. DeVecchio, and F. P. Heinzel. 2003. Modulation of T-cell costimulation as immunotherapy or immunochemotherapy in experimental visceral leishmaniasis. Infect. Immun. 71: 6453-6462.
23. Murugaiyan, G., R. Agrawal, G. C. Mishra, D. Mitra, and B. Saha. 2007. Differential CD40/CD40L expression results in counteracting antitumor immune responses. J. Immunol. 178: 2047-2055. (Pubitemid 46233401)
24. Wadhone, P., M. Maiti, R. Agarwal, V. Kamat, S. Martin, and B. Saha. 2009. Miltefosine promotes IFN-gamma-dominated anti-leishmanial immune response. J. Immunol. 182: 7146-7154.
25. Matzinger, P. 1991. The JAM test. A simple assay for DNA fragmentation and cell death. J. Immunol. Methods 145: 185-192.
26. Corti, B., A. Altimari, E. Gabusi, A. D. Pinna, A. Lauro, A. M. Morselli-Labate, E. Gruppioni, M. G. Pirini, M. Fiorentino, L. Ridolfi, et al. 2005. Potential of realtime PCR assessment of granzyme B and perforin up-regulation for rejection monitoring in intestinal transplant recipients. Transplant. Proc. 37: 4467-4471.
27. Soong, L., J. C. Xu, I. S. Grewal, P. Kima, J. Sun, B. J. Longley, Jr., N. H. Ruddle, D. McMahon-Pratt, and R. A. Flavell. 1996. Disruption of CD40-CD40 ligand interactions results in an enhanced susceptibility to Leishmania amazonensis infection. Immunity 4: 263-273.
28. Aseffa, A., A. Gumy, P. A. Launois, H. R. MacDonald, J. A. Louis, and F. Tacchini- Cottier. 2002. The early IL-4 response to Leishmania major and the resulting Th2 cell maturation steering progressive disease in BALB/c mice are subject to the control of regulatory CD4+CD25+ T cells. J. Immunol. 169: 3232-3241.
29. Anderson, C. F., M. Oukka, V. J. Kuchroo, and D. L. Sacks. 2007. CD4(+)CD25 (-)Foxp3(-) Th1 cells are the source of IL-10-mediated immune suppression in chronic cutaneous leishmaniasis. J. Exp. Med. 204: 285-297.
30. Kim, J., K. Park, H. J. Kim, J. Kim, H. A. Kim, D. Jung, H. J. Kim, H. J. Choi, S. Y. Choi, K. W. Seo, et al. 2008. Breaking of CD8+ T cell tolerance through in vivo ligation of CD40 results in inhibition of chronic graft-versus-host disease and complete donor cell engraftment. J. Immunol. 181: 7380-7389.
31. Murugaiyan, G., S. Martin, and B. Saha. 2007. Levels of CD40 expression on dendritic cells dictate tumour growth or regression. Clin. Exp. Immunol. 149: 194-202.
32. Gold, J. A., M. Parsey, Y. Hoshino, S. Hoshino, A. Nolan, H. Yee, D. B. Tse, and M. D. Weiden. 2003. CD40 contributes to lethality in acute sepsis: in vivo role for CD40 in innate immunity. Infect. Immun. 71: 3521-3528.
33. Rolph, M. S., and S. H. Kaufmann. 2001. CD40 signaling converts a minimally immunogenic antigen into a potent vaccine against the intracellular pathogen Listeria monocytogenes. J. Immunol. 166: 5115-5121.
34. Bachmann, M. F., L. Hunziker, R. M. Zinkernagel, T. Storni, and M. Kopf. 2004. Maintenance of memory CTL responses by T helper cells and CD40-CD40 ligand: antibodies provide the key. Eur. J. Immunol. 34: 317-326.
35. Johnson, S., Y. F. Zhan, R. M. Sutherland, A. M. Mount, S. Bedoui, J. L. Brady, E. M. Carrington, L. E. Brown, G. T. Belz, W. R. Heath, and A. M. Lew. 2009. Selected Toll-like receptor ligands and viruses promote helper-independent cytotoxic T cell priming by upregulating CD40L on dendritic cells. Immunity 30: 218-227.
36. Kumanogoh, A., X. Wang, I. Lee, C. Watanabe, M. Kamanaka, W. Shi, K. Yoshida, T. Sato, S. Habu, M. Itoh, et al. 2001. Increased T cell autoreactivity in the absence of CD40-CD40 ligand interactions: a role of CD40 in regulatory T cell development. J. Immunol. 166: 353-360.
37. Guiducci, C., B. Valzasina, H. Dislich, and M. P. Colombo. 2005. CD40/CD40L interaction regulates CD4+CD25+ T reg homeostasis through dendritic cellproduced IL-2. Eur. J. Immunol. 35: 557-567.
38. Hänig, J., and M. B. Lutz. 2008. Suppression of mature dendritic cell function by regulatory T cells in vivo is abrogated by CD40 licensing. J. Immunol. 180: 1405-1413.
39. Bourgeois, C., B. Rocha, and C. Tanchot. 2002. A role for CD40 expression on CD8+ T cells in the generation of CD8+ T cell memory. Science 297: 2060-2063.
40. Munroe, M. E., and G. A. Bishop. 2007. A costimulatory function for T cell CD40. J. Immunol. 178: 671-682.
41. Sakaguchi, S. 2004. Naturally arising CD4+ regulatory t cells for immunologic self-tolerance and negative control of immune responses. Annu. Rev. Immunol. 22: 531-562.
42. Rabinovich, G. A., D. Gabrilovich, and E. M. Sotomayor. 2007. Immunosuppressive strategies that are mediated by tumor cells. Annu. Rev. Immunol. 25: 267-296.
43. Gurunathan, S., L. Stobie, C. Prussin, D. L. Sacks, N. Glaichenhaus, A. Iwasaki, D. J. Fowell, R. M. Locksley, J. T. Chang, C. Y. Wu, and R. A. Seder. 2000. Requirements for the maintenance of Th1 immunity in vivo following DNA vaccination: a potential immunoregulatory role forCD8+ T cells. J. Immunol. 165: 915-924.
44. Belkaid, Y., C. A. Piccirillo, S. Mendez, E. M. Shevach, and D. L. Sacks. 2002. CD4+CD25+ regulatory T cells control Leishmania major persistence and immunity. Nature 420: 502-507.
45. Wraith, D. C. 2003. Role of interleukin-10 in the induction and function of natural and antigen-induced regulatory T cells. J. Autoimmun. 20: 273-275. (Pubitemid 36677517)
46. Roncarolo, M. G., M. Battaglia, and S. Gregori. 2003. The role of interleukin 10 in the control of autoimmunity. J. Autoimmun. 20: 269-272.
47. Asadullah, K., W. Sterry, and H. D. Volk. 2003. Interleukin-10 therapy - review of a new approach. Pharmacol. Rev. 55: 241-269.